Fadraciclib, a CDK2/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression.

Cell Commun Signal · 2025 · PMC12709703 · PMID 41408267

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

In parallel, γ-H2A.X levels were significantly increased by fadraciclib monotherapy (50 mg/kg) and showed an increasing trend with the fadraciclib-olaparib combination, indicating DNA damage.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.